Drugs and FDA
Zealand and Roche report phase 2 results for petrelintide
Fierce Biotech reported competitive weight loss with petrelintide, but a lackluster effect on blood sugar.
The original reports on this story are listed below.
More top stories
Infectious disease
WHO seeks answers about Russian lab worker’s death
Plague has not been confirmed in the worker’s death, and the WHO is seeking more information from Russia about the cause and testing.
Drugs and FDA
FDA expects mifepristone safety review report by March 2027
The FDA expects to finish its safety study by mid-December and report its findings no later than March 2027.
Vaccines
HHS opens NIH clinic to study vaccine injuries
HHS opened an NIH clinic to study post-vaccination health problems and said it will add patient electronic health records to vaccine-related reports.